Shen Jennifer M, Blank Arthur, Selwyn Peter A
Department of Family and Social Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA.
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):445-7. doi: 10.1097/01.qai.0000185139.68848.97.
Despite advances in treatment, AIDS and its associated comorbidities remain important causes of death. Traditional HIV prognostic markers may be less useful in predicting death in current late-stage patients than in the era before highly active antiretroviral therapy.
We used standardized baseline and follow-up data to describe causes of death and predictors of mortality in a cohort of patients with advanced disease referred to a specialized HIV palliative care program at a large urban medical center.
Of 230 patients, 56% were male with a median age of 43 years; 54% were Hispanic and 39% were African American; 41% had a history of injection drug use; 89% had prior AIDS-defining illnesses; and median baseline values included a CD4 count of 39 cells/mm, HIV viral load of 65,202 copies/mL, Karnofsky score of 30, and 5 impaired activities of daily living (ADL). Over a median follow-up of 126 days (range: 1-823 days), 120 patients died; 54% of these died of late-stage HIV disease and/or bacterial pneumonia or sepsis, 19% of non-AIDS-defining cancers, 13% of liver failure and/or cirrhosis, and 12% of other progressive end-organ disease (eg, cardiac, pulmonary, renal). On multivariate analysis, death was predicted only by age (>65 years), baseline number of ADL impairments, and Karnofsky score (P < 0.0001 for all) and not by any AIDS-specific variables.
For patients with late-stage disease referred to an HIV palliative care program, age and markers of functional status were more predictive of mortality than traditional HIV prognostic variables. Close to half of all deaths were attributable to non-AIDS-specific causes, including cancer and end-organ failure. These findings suggest the need for renewed study of predictors of mortality and prognostic markers in patients with advanced HIV disease and related comorbidities in the HAART era.
尽管治疗取得了进展,但艾滋病及其相关合并症仍是重要的死亡原因。与高效抗逆转录病毒治疗时代之前相比,传统的HIV预后标志物在预测当前晚期患者的死亡方面可能不太有用。
我们使用标准化的基线和随访数据来描述一组转诊至大型城市医疗中心专门的HIV姑息治疗项目的晚期疾病患者的死亡原因和死亡率预测因素。
230例患者中,56%为男性,中位年龄43岁;54%为西班牙裔,39%为非裔美国人;41%有注射吸毒史;89%有既往艾滋病界定疾病;基线中位值包括CD4细胞计数39个/mm,HIV病毒载量65,202拷贝/mL,卡诺夫斯基评分30,以及5项日常生活活动(ADL)受损。中位随访126天(范围:1 - 823天),120例患者死亡;其中54%死于晚期HIV疾病和/或细菌性肺炎或败血症,19%死于非艾滋病界定癌症,13%死于肝衰竭和/或肝硬化,12%死于其他进行性终末器官疾病(如心脏、肺、肾)。多变量分析显示,仅年龄(>65岁)、ADL受损基线数量和卡诺夫斯基评分可预测死亡(所有P<0.0001),而任何艾滋病特异性变量均不能预测。
对于转诊至HIV姑息治疗项目的晚期疾病患者,年龄和功能状态标志物比传统的HIV预后变量更能预测死亡率。近一半的死亡归因于非艾滋病特异性原因,包括癌症和终末器官衰竭。这些发现表明,在高效抗逆转录病毒治疗时代,需要重新研究晚期HIV疾病及相关合并症患者的死亡率预测因素和预后标志物。